创新药板块大幅反弹，关注恒生创新药ETF（159316）、创新药ETF易方达（516080）等产品投资机会

Core Viewpoint - The innovative drug sector is experiencing a rebound, with significant increases in various indices and stocks, driven by positive developments in the industry and favorable macroeconomic conditions [1]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 4.0% as of 10:50 AM, with notable gains from companies such as 3SBio, which increased over 11%, and Innovent Biologics, which rose over 10% [1]. - The CSI Innovative Drug Industry Index increased by 2.9%, with 3SBio hitting a 20% limit-up and Rongchang Biopharma rising nearly 10% [1]. - The Hang Seng Innovative Drug ETF (159316) saw a net subscription of 5 million units during the day, with over 1.5 billion yuan net inflow in the past month, leading among similar products [1]. Group 2: Industry Developments - Recent positive news in the innovative drug industry includes significant collaborations, such as the partnership between Innovent Biologics and Takeda, involving an upfront payment of $1.2 billion, highlighting global market recognition of Chinese innovative drugs [1]. - The innovative drug sector is gaining traction on the international stage, with Chinese companies increasingly showcasing their capabilities [1]. Group 3: Macroeconomic Factors - The Federal Reserve's interest rate cut cycle is generally favorable for innovative drug companies, aiding in financing and valuation expansion, as historical data shows that global pharmaceutical and biotech assets perform well during such periods [1]. - The Hang Seng Hong Kong Stock Connect Innovative Drug Index is a pure index comprising leading innovative drug companies in the Hong Kong stock market, while the CSI Innovative Drug Industry Index focuses on A-share companies involved in innovative drug research and development [1].